\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

••••••••••••	
OMB Number:	3235-0287
Estimated average bur	den
hours per response:	0.5

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addres	1 0	erson*	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC /	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>200211000</u>			MA [VRTX]		Director	10% Owner			
(Last)	(First)	(Middle)		X	Officer (give title below)	Other (specify below)			
C/O VERTEX PHARMACEUTICALS INCORPORATED			3. Date of Earliest Transaction (Month/Day/Year) 08/09/2005		dent & CEO				
130 WAVERLY STREET			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)				X	Form filed by One Re	eporting Person			
CAMBRIDGE	MA	02139	-		Form filed by More than One Reporting Person				
(City)	(State)	(Zip)							
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									

2. Transaction Date 6. Ownership Form: Direct 5. Amount of 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 7. Nature 1. Title of Security (Instr. 3) 2A. Deemed 3. Transaction Execution Date, Securities of Indirect if any (Month/Day/Year) Code (Instr. 8) (Month/Day/Year) 5) Beneficially (D) or Indirect Beneficial Owned Following Ownership (I) (Instr. 4) Reported (Instr. 4) Transaction(s) (Instr. 3 and 4) (A) or (D) Code v Price Amount Common Stock 08/09/2005 Μ 7,100 A \$<mark>9.5</mark> 995,302 D **S**⁽¹⁾ Common Stock 08/09/2005 7,100 D \$15.67 988,202 D shares in Common Stock 207,500 I trust⁽²⁾ Common Stock 10,920 I 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) (Disp of (I	oosed D) tr. 3, 4	Expiration Date (Month/Day/Year) irited r osed) . 3, 4		Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$9.5	08/09/2005		Α			7,100	03/14/1996 ⁽³⁾	12/13/2005	Common Stock	7,100	\$0	1,554,311	D	

Explanation of Responses:

1. Transaction made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.

2. Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.

3. Right to buy under 1994 Stock and Option Plan, vesting quarterly over 5 years from 12/14/95.

Remarks:

Kenneth S. Boger, Attorney-In-

08/10/2005

** Signature of Reporting Person Date

Fact

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.